AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00531973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin
Description: 5-fluorouracil (500 mg/m²) + epirubicin (90 mg/ m²) + cyclophosphamide (500 mg/ m²) + adjuvant radiation therapy ± endocrinological therapy (FEC90)
Study NCT01453361 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil™ Vaccine
Study NCT03352349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressinum
Description: If the PVP is over 12 mmHg after hepatectomy, 1mg of Terlipressinum was given to patients intravenously. If the portal vein pressure is decreased by 1 mmHg, then 2mg of Terlipressinum was continuously given every day in the next 4 days after liver resection.
Study NCT02095886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: BMS-955176
Study NCT04156750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT02966184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: preservative free albuterol
Description: Preservative free albuterol for nebulization
Study NCT00919178 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DEN4 Vaccine Candidate
Description: DEN4 Vaccine Candidate~Participants will receive a single immunization on Study Day 0. Vaccine will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL.
Study NCT00919178 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DEN4 Vaccine Placebo
Description: DEN4 Vaccine Placebo~Participants will receive a single immunization on Study Day 0. Placebo will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL.
Study NCT04024319 — intervention group
Intervention type: PROCEDURE
Intervention: Genicular Nerve Block
Description: 4 ml of local anesthetic were administered in 5 genicular nerves. A total volume of 20 ml were administered in GNB group.
Study NCT03636087 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Access cavity preparation
Description: High speed handpieces will be used with access burs to open the pulp chamber and get access to the root canal system (As a part of conventional root canal treatment established protocol)
Study NCT03636087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Access cavity preparation
Description: High speed handpieces will be used with access burs to open the pulp chamber and get access to the root canal system (As a part of conventional root canal treatment established protocol)
Study NCT01972100 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-level laser therapy (808nm)
Description: Use of low-level laser therapy(LLLT)or placebo-LLLT applied on quadriceps femoris muscles between sets of isokinetic knee flexion-extension exercise
Study NCT01972100 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isokinetic exercise
Study NCT01972100 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo low-level laser therapy
Study NCT02178085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flow imaging
Description: Participants will undergo morphological and then flow MRI. Flow MR images will be processed adequately to obtain quantitative values of arterial and venous flow as well as CSF flow.
Study NCT02737397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMI-001 (SJP-304 and SJP-223)
Study NCT02737397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SJP-304
Study NCT02737397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SJP-223
Study NCT02737397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study NCT03636087 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Working Length Determination
Description: The length of the root canal will be measured using periodical radiographs and Electronic Apex Locators (As a part of conventional root canal treatment established protocol)
Study NCT03636087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Working Length Determination
Description: The length of the root canal will be measured using periodical radiographs and Electronic Apex Locators (As a part of conventional root canal treatment established protocol)
Study NCT03636087 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal instrumentation and chemo-mechanical preparation
Description: Rotary files used to properly instrument and prepare canals length and size (As a part of conventional root canal treatment established protocol)
Study NCT03636087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal instrumentation and chemo-mechanical preparation
Description: Rotary files used to properly instrument and prepare canals length and size (As a part of conventional root canal treatment established protocol)
Study NCT03636087 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal obturation
Description: Gutta Percha filling materials will be used to fill the root canal space with root canal sealer (As a part of conventional root canal treatment established protocol)
Study NCT03636087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal obturation
Description: Gutta Percha filling materials will be used to fill the root canal space with root canal sealer (As a part of conventional root canal treatment established protocol)
Study NCT03636087 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronal restoration build up
Description: A Build up material to seal the accessed tooth properly (As a part of conventional root canal treatment established protocol)
Study NCT03636087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronal restoration build up
Description: A Build up material to seal the accessed tooth properly (As a part of conventional root canal treatment established protocol)
Study NCT03636087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Changing gloves before obturation
Description: The treating dentist will change gloves before obturation
Study NCT03636087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Disinfecting rubber dam
Description: 2.25% Sodium Hypochlorite solution will be used to disinfect the rubber dam surface
Study NCT02737397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01984411 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radial Technical
Description: Vascular Access for cardiac catheterization
Study NCT03267849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wearing swimming goggles or having laser suturelysis
Description: Two images will be compared in each subject at two different eye pressures with the higher pressure having been produced by the interventions
Study NCT01984411 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Technical
Description: Vascular Access for cardiac catheterization
Study NCT03636087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The use of new instruments at time of obturation
Description: A new instrument's kit will be use at the time of obturation
Study NCT01984411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omnipaque
Study NCT01984411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omnipaque
Study NCT03636087 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Cone Beam Computed Tomography scanning (CBCT)
Description: CBCT will be taken before treatment and one year after completion
Study NCT06750445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Patients in the fluoxetine group received oral fluoxetine starting at 40 mg/day for six months. Treatment was discontinued if serious adverse reactions developed or if no improvement was observed after dose escalation. Compliance and treatment progress were monitored via telephone follow-ups. For patients unable to have a bowel movement for three consecutive days or experiencing intolerable symptoms, polyethylene glycol (PEG, 10 g) was provided as rescue medication. Bowel movements within 24 hours of rescue medication use were excluded from the count of complete spontaneous bowel movements (CSBM).
Study NCT06750445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol 400 0.4%
Description: The control group (PEG) used polyethylene glycol as a rescue medication under the same conditions, following similar monitoring and follow-up procedures.
Study NCT01457573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Alpha blocker used to in the treatment of urinary difficulties related to enlarged prostate or symptomatic benign prostatic hypertrophy. All men will receive Tamsulosin (Flomax®) 0.4 mg, 1 tab, per morning with Solifenacin (Vesicare®).
Study NCT01457573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Antispasmodic/anticholinergic used to treat overactive bladder. All men will receive Solifenacin (Vesicare®) 5 mg, 1 tab, per morning with Tamsulosin.
Study NCT03599388 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self- management for adequate sleep intervention (SASI)
Description: Bedtimes and wake times will be prescribed each week for each participant and allow for gradual increases in sleep opportunity. Bedtimes will be set 15 minutes earlier each week provided sleep efficiency remains >90%. Earlier betimes will extend sleep duration by increasing the opportunity for sleep. Wake times will not be changed because wake times are often determined by external demands, such as work schedules
Study NCT03636087 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cone Beam Computed Tomography scanning (CBCT)
Description: CBCT will be taken before treatment and one year after completion
Study NCT03636087 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiographic imaging using periapical radiographs
Description: Periapical radiographs will be taken before, during and one year after the treatment completion (As a part of conventional root canal treatment established protocol)
Study NCT03636087 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiographic imaging using periapical radiographs
Description: Periapical radiographs will be taken before, during and one year after the treatment completion (As a part of conventional root canal treatment established protocol)
Study NCT02508259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suramin
Description: 20 mg/kg IV in 50 ml saline over 30 minutes
Study NCT02508259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 50 ml IV over 30 minutes
Study NCT01780376 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: whole-body vibration (WBV)
Description: whole-body vibration (4 mm amplitude, 25,30,35,40,45,50 Hz)
Study NCT01260337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portion controlled diet
Description: Participants learn skills for changing nutritional and lifestyle habits and diabetes management follow a program that includes eating a pre-packaged, portion controlled meal for weight loss in addition to attending the behavior modification groups
Study NCT01260337 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Support and Education
Description: The DSE groups will consist of educational sessions offered for diabetes support and education which will include sessions on diet/nutrition, exercise, foot care and living with diabetes.
Study NCT03431064 — intervention group
Intervention type: OTHER
Intervention: Lung Recruitment Maneuver
Description: Lung Recruitment Maneuver by Anesthesiologist
Study NCT03431064 — intervention group
Intervention type: OTHER
Intervention: Fluid Administration
Description: Administration of IV Fluid by Anesthesiologist
Study NCT03739216 — intervention group
Intervention type: DEVICE
Intervention: ClariFix
Description: The ClariFix device is a handheld cryosurgical device which provides focal, controlled freezing to the target tissue.
Study NCT01873781 — intervention group
Intervention type: DRUG
Intervention: Cyclopentolatehydrochloride
Description: Cyclopentolatehydrochloride 0.5% (Thilo, Alcon, Vienna), dose: 1 drop for study eye
Study NCT00851409 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Recombinant Human C1 Inhibitor
Description: 50 IU/kg rhC1INH, IV injection over 4 to 5 minutes, once weekly over an 8-week treatment period.
Study NCT01876368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Study NCT01876368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan
Study NCT01876368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of LCZ696
Study NCT01876368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Olmesartan
Study NCT03901157 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt A: Active
Description: Free fat yogurt containing oil-filled alginate gels
Study NCT03901157 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Yogurt B: Control
Description: Free fat yogurt containing the same amount of fat as the active one, and empty alginate gels
Study NCT02812654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 75mg/m2 (cycle 1,2 and 3)
Study NCT02812654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide 9 g/m2 (cycle 1 and 3)
Study NCT02812654 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiotherapy: 25 Gy / 5 x 500 cGy/day
Study NCT04458467 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Infusion
Description: A continuous infusion of ropivacaine 0.2% (6 mL/hr, 4 mL patient controlled bolus with 30-minute lockout) will be initiated in the recovery room.
Study NCT04458467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Intermittent Boluses
Description: Administration of automated intermittent boluses of ropivacaine 0.2% (8 mL every 2 hr with 4 mL patient controlled bolus with 30-minute lockout) will be initiated in the recovery room, but with a 5-hour delay for the first bolus (can be overridden by patients if they would like to initiate their perineural infusion earlier than 5 hours).
Study NCT00647361 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist (NAVA) provided by a commercially available mechanical ventilator (Servo i, Maquet Critical Care, Solna, Sweden).
Description: Neurally adjusted ventilatory assist (NAVA) and pressure support ventilation (PSV)
Study NCT04213482 — intervention group
Intervention type: RADIATION
Intervention: Panoramic Radiography
Description: Diagnostic Panoramic Dental Radiographs were taken.
Study NCT02917733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3039478
Description: Administered orally
Study NCT01570296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib and BKM120
Description: Dose escalation study of gefitinib and BKM120 with expansion cohort
Study NCT03930758 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Behavior intervention of uphill exercise
Description: 40 minutes of uphill exercise
Study NCT03930758 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dietary intervention of exercise before the meal
Description: 40 minutes of uphill exercise completed 1 h before the meal
Study NCT03930758 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dietary intervention of uphill exercise
Description: 40 minutes of uphill exercise
Study NCT03930758 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dietary intervention of exercise after the meal
Description: 40 minutes of uphill exercise started 1 hour after gthe meal
Study NCT03930758 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Behavior intervention of downhill exercise
Description: 40 minutes of downhill exercise
Study NCT03930758 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dietary intervention of exercise before the meal
Description: 40 minutes of downhill exercise completed 1 hour before the meal
Study NCT03761550 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: pMDT(Process Implementation)
Description: The pMDT(Baseline Investigation) takes multi-model analgesia as the main technical means. Multimodal perioperative analgesia refers to the combination of analgesics, adjuvant drugs and analgesic techniques with different effects throughout the perioperative period to achieve the best curative effect of reducing postoperative acute and chronic pain.
Study NCT03564626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health-IT +/- Scheduled Follow Up
Description: * Training patient and caregiver on Patient Buddy and EncephalApp~* Counseling regarding readmission~* Daily contact through app~* Standard of care counseling regarding readmission and discharge instructions~* Follow up phone calls at Week 1 and Week 3~* In-person follow up visits at Week 2 and Week 4
Study NCT03930758 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Behavioral intervention of downhill exercise
Description: 40 minutes of downhill exercise
Study NCT03930758 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dietary intervention of exercise after the meal
Description: 40 minutes of downhill exercise started 1 hour after the meal
Study NCT03930758 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Behavioral intervention of sedentary no-exercise trial
Description: Sedentary no-exercise trial
Study NCT03930758 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Dietary intervention of eating two meals
Description: Meals eaten at 10 and 17 h during a sedentary trial
Study NCT00779740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate
Description: The dose will be 50 mcg as MF in one spray (100 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
Study NCT00779740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone furoate
Description: The dose will be 50 mcg as MF in one spray (50 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
Study NCT03062982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: 2 doses separated by 7 days.
Study NCT02432482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile Positively Smoke Free (mPSF)
Description: mPSF is a targeted, intensive behavioral cessation intervention designed for HIV-infected smokers. It is guided by the Social Cognitive Theory model. It includes 8 weekly sessions of audio/video messages to users, daily text messages, and a variety of other smartphone capabilities, e.g. play-a-tune, play-a-game, phone-a-friend, call the quitline.
Study NCT02432482 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Brief advice to quit (\<5 minutes) Self-help brochure Offer of nicotine patches
Study NCT03488732 — intervention group
Intervention type: DEVICE
Intervention: Transcatheter valvular repair or replacement
Description: Transcatheter valvular repair (predominantly MitraClip for mitral regurgitation) or replacement (predominantly transcatheter aortic valve implantation for aortic stenosis)
Study NCT01477593 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: circumcision with Shenghuan in Yan's method
Description: The foreskin is first separated from the glans.Then the inner ring is placed between them and over the glans. After adjusting the position of inner ring to retain 0.5cm inner foreskin, the operator install the outer ring over the foreskin and combine them together. Removal of excess foreskin is then performed upon the device.
Study NCT01477593 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: circumcision with Shenghuan in Peng's method
Description: The foreskin is first separated from the glans. Then the inner ring is placed on the outer layer of foreskin. Next, the rim of the foreskin is clamped with blood vessel forceps at the 3, 6, 9 and 12 o'clock points. An urologist and an assistant each hold two clamps to widen the opening of the foreskin, and pull it over the inner ring. After the inner and outer layers of the foreskin and the frenulum are symmetrically positioned, the assistant install the outer ring over the foreskin and gently combine it together. Removal of excess foreskin is then performed below the device.
Study NCT01477593 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional method with incision
Description: The procedure of conventional circumcision involve transection of the excess foreskin with reservation of 0.5cm inner foreskin, haemostasis by electrocautery and suture of skin edges with 4-0 absorption sutures.
Study NCT02693119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elamipretide (MTP-131) 1% topical ophthalmic solution
Study NCT02693119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle topical ophthalmic solution
Study NCT03738033 — intervention group
Intervention type: OTHER
Intervention: educational platform
Description: The platform would be opened before they entered the study.